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Introduction {#sec1}
============

Chaperone molecules play a crucial role in cellular homeostasis, stabilizing labile proteins during periods of cellular stress. Heat shock protein 90 (HSP90) is central to the maintenance of cellular homeostasis ([@bib44]), and studies have indicated that HSP90 can bind to 60% of the human kinome and 30% of E3 ubiquitin ligases ([@bib42], [@bib45]). Co-chaperone proteins assist chaperone molecules in their supply and binding of specific client proteins to chaperone molecules ([@bib46]), yet the precise molecular function by which co-chaperones of HSP90 operate is still poorly understood ([@bib42]).

Aryl hydrocarbon receptor (AHR) interacting protein (AIP) is a conserved co-chaperone protein that binds to many proteins, including AHR and HSP90 ([@bib43], [@bib47]). Individuals carrying monoallelic loss-of-function mutations in *AIP* (*AIP* carriers) are predisposed to young-onset, aggressive, usually growth-hormone-secreting pituitary adenomas that often result in acromegalic gigantism ([@bib7], [@bib52]). Our group set out to understand the function of AIP in regulating adaptive immune responses.

Because of the well-described role of AHR regulating T helper 17 (T~H~17) cells ([@bib29], [@bib49]), we started to examine the function of AIP on T cells and used the *Rag1*^*Cre/+*^ mouse strain to study its function in T cells. Unexpectedly, however, we noticed that deletion of *Aip* had an effect on B cells, and we sought to investigate this function in more detail. Germinal centers (GCs) are structures within secondary lymphoid tissues that are vital for the development of effective adaptive immune responses against pathogens ([@bib1], [@bib50]). GCs are challenging environments for lymphocytes. B cells, upon activation, enter GCs where they undergo rapid proliferation, class switch recombination, somatic hyper-mutation, and affinity maturation, all of which place considerable genotoxic stress on B cells ([@bib1], [@bib50]). Inhibitors of HSP90 have been shown to be effective in inducing apoptosis of B cell lymphomas that have a GC origin and overexpress B cell lymphoma-6 (BCL6) protein ([@bib11]).

BCL6 is a master regulator of GC B cell phenotype ([@bib6], [@bib13], [@bib56]). By repressing transcription of pro-apoptotic genes such as *TP53* ([@bib3]), BCL6 enables GC B cells to tolerate genotoxic stress as they undergo rapid proliferation with somatic hyper-mutation and class switch recombination ([@bib3]). Accordingly, BCL6 upregulation is commonly found in B cell lymphomas of GC origin ([@bib2], [@bib3]).

Here, we deleted *Aip* in mouse B cells, which led to suboptimal adaptive immune responses, via altered AKT signaling and by controlling the expression of BCL6 in GC B cells. We show that AIP protects BCL6 from E3 ubiquitin ligase FBXO11-induced proteasomal degradation via binding the deubiquitinase UCHL1. Together, these results demonstrate AIP as a positive regulator of BCL6.

Results {#sec2}
=======

AIP Regulates Adaptive Immune Responses {#sec2.1}
---------------------------------------

To assess the impact of AIP on adaptive immune responses, we crossed *Aip*^*fl/fl*^ mice with *Rag1*^*Cre/+*^ mice generating mice carrying a conditional homozygous deletion of *Aip* in T and B cells (*Aip*^*fl/fl*^;*Rag1*^*Cre/+*^) (referred to as *Aip*^*fl/fl*^ Cre^+^ mice). This resulted in deletion of *AIP* as determined by qPCR and western blot analysis ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). These mice presented no spontaneous signs of pathology from birth to the age when they were used for experiments (9--12 weeks).

To gain insight into whether *Aip* deficiency affected adaptive immunity, *Aip*^*fl/fl*^ Cre^+^ and Cre^−^ littermate controls were immunized with sheep red blood cells (SRBCs) to induce a T cell-dependent immune response and sacrificed 10 days later ([@bib39]). Analysis of the spleen revealed that in contrast to the *Aip*^*fl/fl*^ Cre^+^ animals, there was a significant increase of the GC area or number of GCs in Cre^−^ mouse spleen compared to *Aip*^*fl/fl*^ Cre^*+*^ spleens following SRBC immunization (p = 0.0146) ([Figures 1](#fig1){ref-type="fig"}A--1C).Figure 1AIP Regulates Adaptive Immune Responses(A--C) *Aip*^*fl/fl*^ Cre^+^ (B) and Cre^−^ control (A) mice ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B) were immunized with sheep red blood cells (SRBCs), and 10 days later, the size (A and B) and number of germinal center (GC) B cells (BCL6^+^ area within the IgD^+^ follicle; A and C) was determined. *Aip*^*fl/fl*^ Cre^+^ mice and littermate controls were immunized with NP-KLH absorbed with aluminum hydroxide and examined 14 days after immunization.(D and E) Serum was examined for the ability to bind to antigen with a high-valence (low-affinity) (NP~25~) antigen (D) and a low-valence (high-affinity) (NP~5~) antigen (E).(F) The ratio of NP~5~:NP~25~ affinity antibodies from *Aip*^*fl/fl*^ Cre^+^ and littermate controls was determined. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.Scale bars, 100 μm. Results are from two or three independent experiments with two to four animals per experiment. ^∗^p \< 0.05; ^∗∗^p \< 0.01.

We sought to determine whether *Aip*^*fl/fl*^ Cre^+^ mice had a defect in the ability to generate high-affinity antibodies. Mice were immunized with (4-hydroxy-3-nitrophenyl)-acetyl (NP)-keyhole limpet hemocyanin (KLH) precipitated to aluminum hydroxide (alum), and 2 weeks later, the capacity of serum immunoglobulins to bind to high-valency antigen (NP~25~) and low-valency antigen (NP~5~) was examined ([@bib9]). No difference was detected between the *Aip*^*fl/fl*^ Cre^+^ and Cre^−^ mice in the generation of low-affinity antibody against NP-KLH ([Figure 1](#fig1){ref-type="fig"}D). However, there was a significant reduction in the ability of *Aip*^*fl/fl*^ Cre^+^ mice to produce high-affinity antibody that could bind to NP~5~ (p = 0.0002) ([Figure 1](#fig1){ref-type="fig"}E), and consequently, the ratio between NP~5~ and NP~25~ specific antibodies between *Aip*^*fl/fl*^ Cre^+^ and Cre^−^ mice was low (p = 0.026) ([Figure 1](#fig1){ref-type="fig"}F).

AIP Regulates GC Formation {#sec2.2}
--------------------------

The ability to make antibody responses against T cell-dependent antigens is dependent upon B cell differentiation into GC B cells ([@bib50]). Nonimmunized *Aip*^*fl/fl*^ Cre^+^ had a significantly decreased percentage and ratio of GC B cells (GL7^+^ CD95^+^) (the gating strategy and phenotype are shown in [Figures S1](#mmc1){ref-type="supplementary-material"}C--S1E) compared to littermate controls (p = 0.001) ([Figures 2](#fig2){ref-type="fig"}A--2D). Of particular interest was that *Aip*^*fl/fl*^ Cre^+^ GC B cells demonstrated a significantly lower expression and ratio of BCL6 compared to Cre^−^ GC B cells (p = 0.026) ([Figures 2](#fig2){ref-type="fig"}E and 2F).Figure 2AIP Regulates GC Formation(A--C) GC B cells (B220^+^ GL7^+^ CD95^+^; in A) and percentage of GC B cells from *Aip*^*fl/fl*^ Cre^+^ mice (B; see also [Figures S1](#mmc1){ref-type="supplementary-material"}C--S1F) and ratio of GCs between *Aip*^*fl/fl*^ Cre^+^ and Cre^−^ mice (C).(D and E) Lower expression of BCL6 as determined by flow cytometry (D) measuring the median fluorescent intensity (MFI; in E) (see also [Figures S2--S4](#mmc1){ref-type="supplementary-material"}). Grey histograms represent biological control by gating on naive (IgD^hi^) B cells that do not express BCL6.Results are from two or three independent experiments with two to four animals per experiment. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.

Conversely, *Aip*^*fl/fl*^ Cre^+^ mice displayed a significant increase in the percentage of non-GC B cells in secondary lymphoid tissues (spleen and peripheral lymph nodes) along with increased circulating B cells ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Despite the significant increase in the number of B cells in the spleen, there was no difference in the cellularity of the spleen between Cre^−^ and *Aip*^*fl/fl*^ Cre^+^ mice, as *Aip*^*fl/fl*^ Cre^+^ mice also displayed a decrease in the total number of CD3^+^ T cells ([Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D). Similar to the spleen, we also observed decreased GC B cells and BCL6 expression in peripheral lymph nodes although there was an increase in GC B cells from Peyer's patches in Cre^+^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}A).

Differences in GC B cells may be the result of altered B cell development or the type of B cells produced. Examination of naive, marginal zone and follicular B cell subsets revealed no difference between Cre^−^ and *Aip*^*fl/fl*^ Cre^+^ mice ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3D). BCL6 has been reported to contribute to B cell lymphopoiesis ([@bib16]). Consequently, we examined developing B cell subsets in the bone marrow of Cre^−^ and *Aip*^*fl/fl*^ Cre^+^ mice but found no significant differences ([Figure S3](#mmc1){ref-type="supplementary-material"}C). This indicated that the difference we were observing in *Aip*^*fl/fl*^ Cre^+^ B cells was restricted to GC B cells. However, examination of the bone marrow did reveal a lower percentage of IgM^+^ B220^hi^ B cells from *Aip*^*fl/fl*^ Cre^+^ mice ([Figure S3](#mmc1){ref-type="supplementary-material"}D), suggesting that AIP impacted upon B cells within the bone marrow. We did not observe any changes in the immunoglobulin isotypes in serum or following *in vitro* stimulation of Cre^+^ B cells ([Figure S3](#mmc1){ref-type="supplementary-material"}E), indicating that deficiency of AIP did not alter the production of antibodies or isotype switching.

As AIP was originally described as a co-chaperone for AHR ([@bib32]), we examined *Ahr*^*fl/fl*^ mice crossed with *Rag1*^*Cre/+*^ mice to determine if they had a similar phenotype. In agreement with a publication studying the role of AHR in B cells ([@bib53]), following SRBC immunization, we found no differences in GC B cells, BCL6 expression, or antibody production between *Ahr*^*fl/fl*^;*Rag1*^*Cre/+*^ mice and littermate control mice ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4D). This suggested that AIP was acting independently of AHR to regulate GC B cells and BCL6.

Given the suggested role of AIP in regulating T cell-dependent antigen responses, we tested if there might be a reduced T response to T cell-independent antigens in *Aip*^*fl/fl*^ Cre^+^ mice. To test this, we immunized mice with an NP-Ficoll conjugate, a T cell-independent antigen that recruits marginal zone B cells to produce a low-affinity extra-follicular antibody response ([@bib17]). 10 days after immunization, we analyzed mice and measured the amount of NP-specific immunoglobulin M (IgM), IgG, and IgG3 in the serum by ELISA. *Aip*^*fl/fl*^ Cre^+^ mice could make NP-specific IgM (p = 0.0001) and IgG (p = 0.029) ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B), but the titer of the antibodies against NP was significantly lower compared to Cre^−^ mice. IgG3 is produced in response to T cell-independent antigens ([@bib17]), and *Aip*^*fl/fl*^ Cre^+^ mice made significantly less (p = 0.0031) IgG3 compared to Cre^−^ mice ([Figure S5](#mmc1){ref-type="supplementary-material"}C), despite having normal levels of marginal zone B cells. Examination of the percentage of NP-specific B cells by flow cytometry showed that *Aip*^*fl/fl*^ Cre^+^ mice had significantly decreased percentage of NP-specific plasmablasts (B220^+/−^ CD138^+^) compared to Cre^−^ mice (p = 0.028) ([Figures S5](#mmc1){ref-type="supplementary-material"}D and S5E). Together, these results demonstrated that AIP was required for the generation of development of antibody responses in both the GC and extra-follicular sites.

AIP Regulates GC Organization and AKT Signaling in GC B Cells {#sec2.3}
-------------------------------------------------------------

GC B cells undergo repeated cycles of rapid proliferation in the dark zone (DZ) followed by a resting state in the light zone (LZ) where the cells can reencounter, their antigen presented by follicular-dendritic cells. If the recognition is successful, then B cell progress to become memory B cells or plasmablasts or reenter the DZ to further increase their B cell receptor affinity ([@bib1], [@bib31], [@bib50]). DZ and LZ GC B cells can be distinguished by flow cytometry using the markers including CXCR4 (DZ) and CD86 (LZ) ([@bib51]). Using this method, we analyzed GC B cells and found, in agreement with other studies, a ratio of ∼2 between DZ and LZ B cells in wild-type GC B cells. In contrast, there was a significantly reduced DZ/LZ ratio between *Aip*^*fl/fl*^ Cre^+^ and Cre^−^ mice (p = 0.001) ([Figures 3](#fig3){ref-type="fig"}A and 3B). Immunofluorescent analysis of Cre^−^ and *Aip*^*fl/fl*^ Cre^+^ spleen sections revealed that the area of the DZ (activation-induced deaminase \[AID\]^+^ and BCL6^+^ cells) was smaller in *Aip*^*fl/fl*^ Cre^+^ mice than in Cre^−^ mice ([Figure 3](#fig3){ref-type="fig"}C).Figure 3AIP Regulates GC Organization and AKT Signaling in GC B Cells(A) Expression of dark zone (DZ) (CXCR4^+^) and light zone (LZ) (CD86^+^) GC B cells from immunized *Aip*^*fl/fl*^ Cre^+^ and littermate controls.(B) Ratio of DZ and LZ GC B cells f.(C) Spleen sections from *Aip*^*fl/fl*^ Cre^+^ and Cre^−^ mice were analyzed by immunofluorescence for LZ CD19^+^ BCL6^+^ and DZ AID^+^ BCL6^+^ areas of GCs.(D--F) The phosphorylation of AKT (serine 473) was determined in LZ GC B cells from *Aip*^*fl/fl*^ Cre^+^ and littermate controls (D) and the percentage of pAKT (E) and MFI (F) determined. Grey histograms are gating on IgD^+^ naive B cells used as a biological control.(G and H) IgD^−^ B cells from Cre^+^ and Cre^−^ mice were stimulated with anti-IgM (10 μg/mL) and examined for the expression of phosphorylated AKT from 5 to 60 min post-stimulation (G) and the percentage increase from time zero determined (H). See also [Figure S6](#mmc1){ref-type="supplementary-material"}. Grey histograms show expression at time zero (T0).Scale bars, 50 μm. Results are from two or three independent experiments with one or two mice per experimental group. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.

Phosphatidylinositol 3-kinase (PI3K) signaling contributes to the segregation of the DZ and LZ by phosphorylating AKT (serine 473) in LZ GC B cells, resulting in decreased expression of the chemokine receptor CXCR4 ([@bib14], [@bib39]). We observed a significant decrease in phospho-AKT expression in LZ GC B cells from *Aip*^*fl/fl*^ Cre^+^ mice compared to Cre^−^ mice (p = 0.003) ([Figures 3](#fig3){ref-type="fig"}D--3F). AIP appeared to regulate the AKT pathway, as *in vitro* anti-IgM stimulation of *Aip*^*fl/fl*^ Cre^+^ B cells revealed that while AKT was rapidly phosphorylated in both *Aip*^*fl/fl*^ Cre^+^ and Cre^−^ deficient B cells following stimulation, AKT phosphorylation was subsequently reduced at a faster rate in Cre^+^ B cells than in Cre^−^ B cells ([Figures 3](#fig3){ref-type="fig"}G and 3H). AIP appeared to be specifically regulating AKT, as the extracellular signal regulated kinase (ERK) and SYK pathways were unaffected ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B).

AIP Regulates GC B Cells Independently of T Cells {#sec2.4}
-------------------------------------------------

As we had conditionally deleted *Aip* in both T and B cells, it raised the possibility that the defects observed in *Aip*-deficient B cells might be consequent to altered T cell help. We observed a decrease in T follicular helper (T~FH~) cells in *Aip*^*fl/fl*^ Cre^+^ mice (data not shown). T~FH~ cells are dependent on BCL6 for their development ([@bib20]), and we observed a decrease in BCL6 expression in *Aip*^*fl/fl*^ Cre^+^ mice (data not shown). To address this issue, we crossed *Aip*^*fl/fl*^ mice with Cγ1-Cre mice to specifically delete *Aip* in GC B cells ([@bib8]). Mice were immunized with SRBCs, and 10 days later, the percentage of GC (GL7^+^ CD95^+^) B cells and the expression of BCL6 were determined. As predicted, conditional deletion of *Aip* in GC B cells resulted in a lower percentage of GC B cells with a lower expression of BCL6 ([Figures 4](#fig4){ref-type="fig"}A--4D) and a decreased ratio of DZ to LZ GC B cells ([Figure 4](#fig4){ref-type="fig"}E) and decreased anti-SRBC IgG ([Figure 4](#fig4){ref-type="fig"}F). Together, these results indicated that AIP regulated GC B cells and BCL6 expression independently of T cells.Figure 4AIP Regulates GC B Cells Independently of T Cells(A and B) GC B cells (GL7^+^ CD95^+^) from *Aip*^*fl/fl*^ mice crossed with *Cγ1*^*Cre/+*^ mice and examined at baseline (open circles) or following immunization with 2 × 10^9^ SRBCs (filled circles) 10 days later (A) and the expression of BCL6 was assessed by flow cytometry (B).(C and D) The percentage of GC B cells (C) and MFI from baseline (unimmunized; D) and immunized *Aip*^*fl/fl*^; *Cγ1*^*Cre/+*^ mice was determined.(E) Expression and ratio of DZ (CXCR4^+^) and LZ (CD86^+^) GC B cells from immunized mice.(F) Serum anti-SRBC IgG determined by incubating serially diluting serum from Cre^−^ and Cre^+^ mice.Results are from two independent experiments with three mice per group. ^∗^p \< 0.05; ^∗∗^p \< 0.01.

AIP Protects BCL6 from FBXO11-Mediated Proteasomal Degradation {#sec2.5}
--------------------------------------------------------------

We sought to investigate the mechanism by which AIP sustains BCL6 expression in GC B cells. The E3 ligase containing F box protein O11 (FBXO11) has been shown to target BCL6 for ubiquitin-mediated proteasomal degradation ([@bib15]). This observation attracted our interest as a potential mechanism by which AIP could regulate BCL6, as AIP had previously been shown to protect AHR from ubiquitin-mediated degradation ([@bib22]) and AIP has recently been found to bind to FBXO3 ([@bib18]). We hypothesized that AIP was protecting BCL6 from ubiquitin-mediated proteasomal degradation via FBXO11.

Immunoprecipitation (IP) analysis of HEK cells transfected with MYC-tagged AIP and FLAG-tagged FBXO11 revealed that AIP could bind to FBXO11 and BCL6, thereby revealing a potential mechanism of action ([Figures 5](#fig5){ref-type="fig"}A and 5B). Ubiquitin E3 ligases are often found in association with deubiquitinases (DUBs) of the same substrate ([@bib23]). We therefore wanted to know if AIP associated with any DUBs that might regulate BCL6 expression. Mass-spectrometry analysis had revealed that AIP could bind to the DUB UCHL1 ([@bib18]). UCHL1 is induced in GC B cells and cooperates with BCL6 to promote a mouse model of lymphoma and is associated with an aggressive subset of diffuse large B cell lymphoma (DLBCL) ([@bib4], [@bib21]). We hypothesized that AIP might support the expression of BCL6 by binding UCHL1 and support the deubiquitination of BCL6.Figure 5AIP Protects BCL6 from FBXO11-Mediated Proteasomal Degradation(A) HEK293T cells were transfected with either a FLAG-tagged FBXO11 or empty vector (EV-FLAG), together with MYC-tagged AIP. A majority of the whole-cell extracts (WCEs) were subjected to immunoprecipitation (IP) using FLAG antibody (rows 1 and 2), and the rest of the WCEs were used in immunoblotting (rows 3 and 4).(B) HEK293T cells were transfected with either FLAG-tagged BCL6 or EV-FLAG, together MYC-tagged AIP ([@bib28]). A majority of the WCEs were subjected to IP using FLAG antibody (rows 1 and 2), the and the rest of the WCEs were used in immunoblotting (rows 3 and 4).(C) OCI-LY7 DLBCL cells were lysed and immunoprecipitated with antibodies to IgG, AIP, UCHL1 and immunoblottedfor AIP and UCHL1.(D) OCI-LY7 DLBCL cells were lysed and immunoprecipitated with antibodies to IgG, BCL6, UCHL1 and immunoblotted for BCL6 and UCHL1.(E) OCI-LY7 DLBCL cells were lysed and immunoprecipitated with antibodies to IgG, FBXO11 and BCL6 and immunoblotted for BCL6 and FBXO11. β-actin was used as a loading control.(F) HEK293T cells were transfected with MYC-tagged AIP or EV-MYC, FLAG-tagged FBXO11, HIS-tagged BCL6, and hemagglutinin (HA)-tagged ubiquitin. Where indicated, cells were treated with MG132 post-transfection for 2.5 h to inhibit proteasomal degradation.(G) HEK cells were transfected as in (F) and FLAG-tagged UCHL1. Cells were harvested and subjected to IP BCL6. Corresponding WCEs are shown.(H) OC1-LY7 cells were stained with AIP, BCL6, UCHL1, and FBXO11. DAPI was used as a nuclear stain. Arrowheads show areas of co-localization.

Using the functionally relevant DLBCL cell line OCI-LY7, we found that AIP could bind to UCHL1 ([Figure 5](#fig5){ref-type="fig"}C) and that UCHL1 could bind to BCL6 ([Figure 5](#fig5){ref-type="fig"}D), indicating that UCHL1 could be responsible for maintaining BCL6 expression. In agreement with [@bib15], we found that OCI-LY7 cells expressed FBXO11, although interestingly, using these cells, we found that FBXO11 could not directly bind to BCL6 ([Figure 5](#fig5){ref-type="fig"}E). To determine if FBXO11-mediated degradation of BCL6 could be modulated by AIP, we transfected HEK cells with epitope-tagged FBXO11, BCL6, AIP, and ubiquitin plasmids. The addition of AIP reduced FBXO11-mediated ubiquitin conjugation to BCL6. The absence of AIP resulted in an increase in BCL6 ubiquitination (in the presence of FBXO11) and subsequently decreased BCL6 expression, recapitulating what we observed in *Aip*-deficient B cells ([Figure 5](#fig5){ref-type="fig"}F).

BCL6 has not been described as being a substrate for UCHL1, so we tested whether UCHL1 could deubiquitinate BCL6. Transfection of HEK cells revealed that UCHL1 could deubiquitinate BCL6 only in the presence of AIP ([Figure 5](#fig5){ref-type="fig"}G), indicating that AIP regulated the function of UCHL1. To confirm the IP results, we performed confocal microscopy using the OC1-LY7 lymphoma cell line. AIP co-localized with BCL6, UCHL1, and FBXO11. BCL6 co-localized with FBXO11 and, to a greater extent, UCHL1 ([Figure 5](#fig5){ref-type="fig"}H). Together, these results revealed the mechanism by which AIP regulated BCL6 expression in GC B cells.

AIP Is Overexpressed in Human DLBCLs {#sec2.6}
------------------------------------

Examination of the cbioportal database for cancer genomics (<http://www.cbioportal.org>; [@bib10]) revealed that *AIP* expression was higher in DLBCLs than in other cancers and tumors ([Figure 6](#fig6){ref-type="fig"}A). Histological analysis of primary DLBCL biopsy samples revealed that AIP expression was significantly increased compared to control (reactive lymph node) samples (p \< 0.0001) ([Figure 6](#fig6){ref-type="fig"}B). Data obtained from genomicscape (<http://www.genomicscape.com/>) revealed that DLBCL patients with high *AIP* expression had significantly (p = 0.002) reduced survival compared to those with low *AIP* expression, indicating that increased *AIP* expression contributed to the morbidity of DLBCL ([Figure 6](#fig6){ref-type="fig"}C). Western blot analysis revealed that AIP was expressed in a number of DLBCL cell lines and that its expression matched BCL6 expression ([Figures 6](#fig6){ref-type="fig"}D and 6E).Figure 6AIP Is Overexpressed in Human DLBCLs(A) *AIP* is expressed in many tumors, and *AIP* was found to be most highly expressed in DLBCLs. Data were obtained from <http://www.ciobioportal.org>.(B) AIP staining from reactive lymph nodes (n = 88 mean 13 ± 2.5) and DLBCL biopsies (n = 74 mean 20 ± 2.5) ^∗∗∗^p \< 0.0001 (two-tailed Mann-Whitney U test).(C) Survival analysis of DLBCL patients with high and low AIP expression. Data obtained from <http://www.genomicscape.com/>.(D) BCL6 and AIP protein expression in DLBCL cell lines.(E) Ratio between AIP and BCL6 expression. EBV, Epstein-Barr-virus-infected B cells; PB, peripheral blood B cells.(F) Lentiviral delivery of scrambled or shRNAi against *Aip* to OC1-LY7 cells. Cells were examined 48 h after transfection, and the expression of AIP and BCL6 and cell viability were analyzed by flow cytometry.(G) Diagram showing the interaction between FBXO11, UCHL1, BCL6, and AIP. Under genotoxic environments found in GC B cells or DLBCL cells, AIP brings UCHL1 to deubiquitinate BCL6, thus maintaining its expression. In the absence of AIP, BCL6 gets ubiquitinated by FBXO11 and undergoes proteasomal degradation. ^∗∗∗^p \< 0.0001 (a Mann-Whitney U test).

To determine if knockdown of *AIP* in lymphoma cells affects their viability, we performed lentiviral knockdown of AIP in OC1-LY7 DLBCL lymphoma cells. Knockdown of *AIP* in OC1-LY7 cells resulted in decreased AIP and BCL6 expression and decreased the viability of the DLBCL lymphoma cells ([Figure 6](#fig6){ref-type="fig"}F).

Based upon these results, we propose that AIP positively regulates BCL6 expression by binding to the DUB UCHL1, thereby preventing FBXO11-mediated ubiquitination of BCL6 and contributing to the maintenance of BCL6 expression in GC B cells and DLBCLs ([Figure 6](#fig6){ref-type="fig"}G).

Discussion {#sec3}
==========

Lymphocytes need to maintain cellular homeostasis as they navigate a range of genotoxic events and environments. A particularly challenging environment is within GCs, where B cells undergo rapid proliferation, class switching, and somatic hyper-mutation. How B cells preserve cellular homeostasis in this environment is still not completely clear.

We provide evidence that AIP is required for mounting immune responses against T cell-dependent and, to a lesser extent, T cell-independent antigens and the generation of high-affinity antibodies. Consequently, we found that *Aip*^*fl/fl*^ Cre^+^ mice and conditional deletion of *Aip* in GC B cells display a significant reduction in the percentage of GC B cells and decreased BCL6 expression, partly providing an explanation for impaired adaptive immune responses.

We focused on AIP regulation of BCL6, as it was an obvious starting candidate when we observed decreased GC B cells in *Aip*^*fl/fl*^ Cre^+^ mice. In line with our observations, *Bcl6*-deficient mice have impaired GC responses similar to the phenotype we observed ([@bib20], [@bib56]). However, not all the effects that we see in our *Aip*^*fl/fl*^ Cre^+^ mice can be attributed to decreased expression of BCL6; for example, reduced extra-follicular immune responses and reduced AKT phosphorylation are not features of *Bcl6*-deficient mice, and to our knowledge, BCL6 is not known to regulate the migration of B cells.

*Aip*-deficient B cells initially phosphorylated AKT similar to wild-type B cells; however, AKT phosphorylation was rapidly lost in *Aip*-deficient B cells in contrast to wild-type B cells. We have observed similar defects in AKT signaling following insulin stimulation in GH3 pituitary cells with lentiviral *Aip* knockdown (M.K. and O.H., unpublished data). HSP90 has been found to regulate AKT expression and phosphorylation ([@bib40]), and UCHL1 has also been found to regulate AKT signaling ([@bib21]), and we are currently determining how AIP regulates AKT signaling.

AIP is a co-chaperone for AHR ([@bib22], [@bib27]). We were therefore surprised to find that conditional deletion of *Ahr* in B and T cells did not match the phenotype we observed in *Aip*^*fl/fl*^ Cre^+^ mice. This indicated that AIP was acting independently of AHR to regulate GC B cells. This finding is supported by Villa et al., who showed that AHR supported B cell proliferation but was not necessary for T cell-dependent or independent immune responses ([@bib53]). However, a recent publication reports that AHR was important in suppressing T cell-dependent and T cell-independent immune responses ([@bib48]). The reasons for the different responses from *Ahr* null B cells are not clear at present.

As BCL6 is an important oncoprotein, there is considerable interest in how it is regulated. BCL6 expression can be controlled via post-translational mechanisms, including phosphorylation ([@bib34]), mRNA stability, and nuclear export by eIF4Ae (eukaryotic translation initiation factor 4E) ([@bib12]), in response to DNA damage ([@bib37]) and stabilization by HSP90 ([@bib11]). Mitogen-activated protein kinase (MAPK) signaling following B cell receptor stimulation has been shown to be involved in the degradation of BCL6 ([@bib34]). We saw no evidence of increased ERK signaling in *Aip* null B cells compared to wild-type B cells following anti-IgM stimulation, suggesting that this is not the mechanism by which AIP regulated BCL6 expression.

FBXO11 has been found to target BCL6 for ubiquitin-mediated degradation and mutations in FBXO11 associated with lymphoma ([@bib15]). We found that AIP and the FBXO11-containing E3 ligase complex co-immunoprecipitation (co-IP), and we demonstrated that AIP inhibited FBXO11-mediated ubiquitination of BCL6. Intriguingly, mice deficient for FBXO11 in their B cells show a phenotype that is the opposite of ours; namely, an increased percentage of GC B cells and DZ GC B cells. These mice are also more prone to developing lymphoproliferative disease ([@bib41]). The DUB UCHL1 has been found to be expressed in GC B cells and lymphoma cells ([@bib21]), but the functional relevance of this expression of UCHL1 has not been determined. We found that UCHL1 could deubiquitinate BCL6, but only in the presence of AIP, indicating that AIP regulated the function of UCHL1. The precise mechanism by which AIP regulates UCHL1 will be the focus of future research, but DUBs often require co-factors to function ([@bib23]).

AIP is a co-chaperone of HSP90 that can bind to proteins that control GC B cell phenotype, including c-MYC, STAT5, and nuclear factor κB (NF-κB), in addition to BCL6 ([@bib11], [@bib19], [@bib35], [@bib54]). We have not ruled out the possibility that AIP can regulate these molecules, as these might contribute to the phenotype we observe in *Aip*-deficient B cells. This is the focus of ongoing research.

Ubiquitin E3 ligases often work in close proximity to DUBs to provide precise control over substrate proteins ([@bib23]). Increased expression of the DUB UCHL1 has been associated with development of lymphoma and is a positive regulator of AKT signaling ([@bib4], [@bib21]), but in B cells, its substrates and how it is regulated have not been identified. We found UCHL1 to be a binding partner of AIP and BCL6, indicating that it might function to help maintain BCL6 expression in GC and DLBCL cells.

There is significant evidence that chaperones are important regulators of protein quality control, helping ubiquitin E3 ligases and DUBs recognize their target proteins ([@bib24], [@bib26], [@bib30], [@bib33], [@bib36]). Chaperone molecules contribute to the pathobiology of cancers by protecting labile proteins from being degraded and supporting signaling pathways that cancer cells are dependent upon ([@bib38], [@bib55], [@bib57]). We found AIP to be predominantly expressed in DLBCL compared to other tumors and overexpressed in DLBCL biopsy samples compared to tonsil tissue, indicating that AIP might contribute to DLBCL pathology. Knockdown of *AIP* in DLBCL cells resulted in decreased viability of DLBCL cells, indicating that targeting AIP could be used as a potential treatment for DLBCL.

How BCL6 expression is maintained is still not completely understood. The data presented here reveal that AIP is a positive regulator of BCL6 protein expression, which is commonly upregulated in B cell lymphomas, and show that AIP binds to an E3 ligase (FBXO11) and a DUB (UCHL1), both of which have been associated with DLBCL pathobiology. Therefore, AIP is a potential therapeutic target to treat DLBCLs.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**CD16/32 Supernatant harvested from hybridomaRaulet Lab, UC, BerkeleyN/AB220 FITC clone RA3-6B2BiolegendAB_312990CD4 APC clone GK1.5BiolegendAB_312696CD3e AF700 clone145-2C11Thermo Fisher Scientific (eBioscience)AB_837094CD21/35 clone eBio8D9Thermo Fisher Scientific (eBioscience)AB_10855041CD23 PE-Cy7 clone B3B4BiolegendAB_2103037CD38 BV421 clone 90Thermo Fisher Scientific (eBioscience)AB_11218302CD95 PE clone 15A7Thermo Fisher Scientific (eBioscience)AB_465788CD83 eFluor450 clone Michel-19BiolegendAB_2566123CD138 PE clone 281-2BiolegendAB_10915989IgD APC clone11-26cThermo Fisher Scientific (eBioscience)AB_10598660IgM eFluor 450 clone eB121-15F9Thermo Fisher Scientific (eBioscience)AB_10671539CD24 APC clone M1/69Thermo Fisher Scientific (eBioscience)AB_2534261CD43 PE clone eBioR2/60Thermo Fisher Scientific (eBioscience)AB_465659CXCR4 PerCP clone L276F12BiolegendAB_2562786Rat anti CD19 eFlour660 clone eBio1D3Thermo Fisher Scientific (eBioscience)AB_657650CD86 PE-Cy7 clone GL1Thermo Fisher Scientific (eBioscience)AB_2573372GL-7 Pacific Blue clone GL-7BiolegendAB_2563291AIPNovus BiologicalsAB_10002466BCL6 PerCP clone BCL-DWNThermo Fisher Scientific (eBioscience)AB_2573767BCL6CSTAB_10949970FBXO11Bethyl LaboratoriesAB_890603UCHL1ProteintechAB_2210497pAKT eFluor 450 clone SDRNRThermo (eBioscience)AB_2574125p-ERK PEThermo Fisher Scientific (eBioscience)AB_2572695p-SYK PEThermo Fisher Scientific (eBioscience)AB_2572675Anti-mouse IgG biotinThermo Fisher Scientific (eBioscience)AB_466650Anti-mouse IgMJackson LaboratoryAB_2340761Anti-mouse CD40 clone 1C10BiolegendAB_312942Rabbit anti BCL6 clone N-3Santa CruzAB_2063450Rat anti-mouse IgD APC clone 11-26c.2aBD BiosciencesAB_10612002Anti-mouse IgM FITCSouthern BiotechAB_2687524Goat goat anti-mouse IgG~1~ Alexa Flour 647Life TechnologiesAB_141658Goat anti-mouse IgG~2a~ Alexa Flour 647Life TechnologiesAB_141698**Bacterial and Virus Strains**pHIV1 lentivirus plasmidBarts Cancer InstituteN/ApVSV-G lentivirus plasmidBarts Cancer InstituteN/ABiological SamplesHuman DLBCL tissue microarray for 33 patientsBarts Cancer Institute Tissue BankN/A**Chemicals, Peptides, and Recombinant Proteins**Sheep Red Blood CellsTSC BiosciencesCat \# SB069NP-PEBiosearch TechnologiesCat \# N-5070-1NP-BSABiosearch TechnologiesCat \# N-5050XL-10NP-Keyhole Limpet HemocyaninBiosearch TechnologiesCat \# N-5060-5Recombinant mouse IL-4PeprotechCat \# 214-14**Experimental Models: Cell Lines**HEK293TATCCCRL-3216OC1-LY7ATCCACC688SUDHL6Barts Cancer InstituteN/AOC1-LY1Barts Cancer InstituteN/ADoHH2Barts Cancer InstituteN/AKarpas422Barts Cancer InstituteN/AA20Barts Cancer InstituteN/AEBV of healthy controlKorbonits Lab ([@bib18])N/A**Experimental Models: Organisms/Strains**Aip flox/flox miceJackson Laboratories013195Ahr flox/flox miceStockinger Lab, Crick Institute, London ([@bib29])N/ARag1 Cre miceStockinger Lab, Crick Institute, London ([@bib29])N/ACγ1 Cre miceCalado Lab, Crick Institute, London ([@bib8])N/A**Oligonucleotides***Rag1* KI CRE F: 5′-TTTGTTTTTGTTTGCTTGTTTGASigmaN/A*Rag1* WT R: 5′-ATCCTTCTCCTTCTGTGCTTCTTSigmaN/A*Rag1* KI CRE (V2): 5′-AATGTTGCTGGATAGTTT\
TTACTGCSigmaN/A*Cγ1* IgG1 Kpn1 (WT): 5′ -TGTTGGGACAAACG\
AGCAATCSigmaN/A*Cγ*1 Cre Cre13 (CRE) 5′-GGTGGCTGGACCAA\
TGTAAATASigmaN/A*Cγ1* Cre IgG1Rev (Common) 5′-GTCATGGCAAT\
GCCAAGGTCGCTAGSigmaN/A*Aip*: F 5′-CAATCCCCCACTGTCACTTSigmaN/A*Aip*: R- 5′-TCACCCCTCCCACTGACTACSigmaN/A*Aip Smart vector lentiviral shRNA*DharmaconN/A**Recombinant DNA**AIP-MYC pcDNA3.1Korbonits Lab ([@bib28])N/ABCL6-FLAG pcDNA3.1SinoBiologicalCat \# NM_138931FBXO11-FLAG pCMV3SinoBiologicalCat \# BC130445Ub-HA pRK5Nightingale Lab (QMUL, London)N/AUCHL1-FLAGSinoBiologicalCat \# NM_004181.4**Software and Algorithms**PRISM version 6Graphpad.comN/AFlowJo Version 9.3.1Tree StarN/AAriol SoftwareLeica BiosystemsN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Oliver Haworth (<o.haworth@westminster.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Mice {#sec4.3.1}

*Aip*^*fl/fl*^ (Jackson laboratories) and *Ahr*^*fl/fl*^ mice ([@bib29]) were crossed with *Rag1*^*Cre/+*^ mice (a kind gift from Brigitta Stockinger, Crick Institute) to specifically delete *Aip* in *Rag1* expressing cells (T and B cells) as previously described ([@bib29]), and Cγ1^Cre/+^ mice (a kind gift from Dinis Calado, Crick Institute; [@bib8]) to specifically delete *Aip* in GC B cells. Male and female mice were born to expected Mendelian ratios and had no signs of any abnormalities until they were used at 9-11 weeks of age. Male and female mice were randomly assigned to experimental groups. All mice were maintained in a barrier facility and all experiments were approved and performed adhered to Home Office regulations (Guidance on the Operation of Animals, Scientific Procedures Act, 1986) and Queen Mary University of London ethics committee on the use of animals for research. Genotyping was performed using the primers listed in [Key Resources Table](#sec4.1){ref-type="sec"}.

### Cell lines {#sec4.3.2}

HEK293T (ATCC), OC1-LY7 (ATCC), SUDHL6, OC1-LY1, DoHH2, Karpas422, A20 (Barts Cancer Institute), human EBV ([@bib18])

### Tissue array {#sec4.3.3}

Human DLBCL tissue microarray (33 patients, age range 23-86y). Sample collection approved by the local Human Ethics Committee.

Method Details {#sec4.4}
--------------

### Immunizations {#sec4.4.1}

Mice were immunized in the peritoneum with either 2 × 10^9^ fresh SRBCs (TSC Biosciences Ltd, UK) and 10 days later sacrificed as in [@bib8]. NP (4-hydroxy-3-nitrophenyl-acetyl) conjugated to Keyhole Limpet Hemocyanin (KLH) or to Ficoll (Biosearch Technologies, Petaluma, USA) and examined 14 days later ([@bib9], [@bib17]).

### Collection and staining of tissues {#sec4.4.2}

Mouse tissues were stained using primary antibodies ([Key Resources Table](#sec4.1){ref-type="sec"}). Nuclei were detected using Hoechst 33258 and FITC was amplified using goat anti-FITC Alexa Flour 488 (Life Technologies). For AID staining a tertiary step of donkey anti-goat FITC (Jackson ImmunoResearch) was used. Slides were imaged using the Zeiss LSM 780 Confocal Microscope and Zeiss Axio Scan.Z1. Image analysis was performed using Zeiss Zen 2012 software to determine germinal center, follicular and spleen area. Plasma cells were counted by hand.

### IgM stimulation of B cells {#sec4.4.3}

Spleen cells were stimulated with anti-mouse IgM (10μg/ml) (Jackson ImmunoResearch). At the end of the experiment, cells were immediately put on ice, fixed and permeabilized using and analyzed by flow cytometry for phosphorylated signaling molecules.

### *In vitro* cell culture of B cells {#sec4.4.4}

B cells were isolated by MACS isolation or cell sorting and 10^5^/well were stimulated with 1 μg/ml anti-CD40 (Jackson ImmunoResearch) and 25ng/ml IL-4 (eBioscience) and the cells examined 38, 72 and 96 hours after stimulation.

### Flow cytometry {#sec4.4.5}

Single-cell suspensions of tissues were prepared by passing spleen and lymph nodes through a 70 μm cell strainer and incubated with anti-CD16/32 (2.4G2) to block non-specific binding and then stained with antibodies ([Key Resources Table](#sec4.1){ref-type="sec"}). Cells were fixed and permeabilized using the Biolegend intracellular staining and permeabilization buffer according to the manufacturer's instructions. Samples were acquired on an LSR Fortessa (BD) and the data analyzed using FlowJo software version 9.3.1 (Tree Star, Inc, Ashland, USA).

### Detection of sheep red blood cell-specific antibodies {#sec4.4.6}

This was performed as described in [@bib8]. Serum from mice was serially diluted and incubated with SRBC for 20 minutes on ice washing in cold phosphate-buffered saline and staining the SRBCs with a phycoerythrin (FITC)-conjugated anti-mouse IgG antibody and the samples were analyzed by flow cytometry.

### Western blotting {#sec4.4.7}

Cells were re-suspended in cold RIPA lysis buffer (50mM Tris-HCl, pH 8.0, 10% sodium deoxycholate, 10% SDS, 150mM NaCl, 5mM EDTA, pH 8.0), supplemented with a mixture of protease inhibitors (1mM phenylmethylsulphonyl fluoride, 10mM sodium fluoride, 1mM sodium vanadate, 1mg/mL Leupeptin, 2mg/ml Aprotinin, 1M B-glycer). Samples were separated by standard SDS-polyacrylamide gel electrophoresis (SDS--PAGE). Protein extracts (40 μg total protein/lane) were fractionated on 8% SDS polyacrylamide gels and transferred to nitrocellulose membranes before being incubated with primary antibodies.

### Immuno-precipitation {#sec4.4.8}

HEK293T cells (ATCC) (0.5 × 10^6^) were plated in 10cm dishes and the next day transfected with AIP and BCL6 epitope tagged plasmids using Fugene (Promega) according to the manufacturer's instructions. The next day, cells were washed with 1ml phosphate-buffered saline and lysed using lysis buffer (5M NaCl, 1M Tris, 75% glycerol, 0.5M, EDTA, NP-40, sodium fluoride, dH~2~O and sodium vanadate). Subsequently, the cell lysates underwent immune-precipitation executed under cold conditions (4°C) throughout. Cell lysates were subjected to an overnight incubation on a rotator with the primary antibody followed by a two-hour incubation with 50 μL of protein A and G agarose beads. Pellets were washed with 500 μL lysis buffer five times, re-suspended in 40 μL lysis buffer and 10 μL 4 × SDS sample buffer. Samples were boiled at 95°C for 5 minutes and left to cool on ice to proceed with SDS-PAGE for immuno-blotting.

### AIP staining of DLBCL tissue biopsies {#sec4.4.9}

Tissue microarrays containing either reactive lymph node (tonsil) or DLBCL samples from the Bart's Cancer Institute tissue bank were immuno-stained for AIP and tissue microarrays images were taken using an Olympus BX61 microscope and analyzed using Ariol software for the staining intensity of AIP.

### Lentivirus production and transfection of B cells {#sec4.4.10}

Lentivirus was produced using the protocol described in [@bib25] in accordance with institutional guidelines using lentivirus. ShRNAi sequences against human *AIP* were purchased from Dharmacon/GE Life sciences. Early passage OC1-LY7 cells (less than passage 10) (ATCC) grown in Iscove's Modified Dulbecco's Medium supplemented with 20% FBS, were transduced with lentivirus containing a scrambled sequence or shRNAi against *AIP* using the method described by [@bib5]. 2.5 × 10^5^ OC1-LY7 cells were spin-oculated with 50 μL of lentivirus supernatants supplemented with 5mg/ml polybrene (Sigma) and spun for 90 minutes at 2300 rpm. After 4 hours, media was replaced with fresh media (Iscove's modified Dulbecco's Medium supplemented with 10% FBS) and 24 hours later the cells were examined. Transfection efficiency using green fluorescent protein was shown to be ∼85%.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Statistical analysis was performed using Prism software (Version 6). Un-paired two-tailed Student's t test, Mann-Whitney test and 2-way ANOVA test were used as appropriate. Significance was taken as p \< 0.05. Statistical details of the experiments can be found in the Figure Legends and [Results](#sec2){ref-type="sec"}. Data are plotted as mean ± SEM with *n* the number of biological replicates. On figures significance is marked as ^∗^ p \< 0.05, ^∗∗^ p \< 0.01, ^∗∗∗^p \< 0.001.
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